-
ImmuPharma to present live on ‘Investor Meet Company’ platform Friday 20 March 2026 @ 12:00 (GMT)
ImmuPharma PLC (LSE AIM:), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics is pleased to announce that ImmuPharma’s Tim McCarthy, CEO, Dr Sébastien Goudreau, CSO, and Dr Tim Franklin, COO, will provide a live presentation relating to the Company’s announcement, released on Tuesday 17 March 2026, titled: P140 Update – remains on track…
-
Proactive
ImmuPharma CEO on P140 progress and expanded pipeline with Kapiglucagon 17 March 2026 ImmuPharma PLC (AIM:IMM, FRA:25I) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company’s latest developments, including progress on its lead asset P140, a newly accelerated program for Kapiglucagon, and recent fundraising activity. – March 2026
-
WRAP Retail Offer for up to £1.5 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION…
-
P140 Update; Fundraise, Related Party Transaction
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2026 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2020 (UK MAR). ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS…
-
TR-1: Standard form for notification of major holdings
TR-1: Standard form for notification of major holdings from Luca & Associates AG To download form Click here
-
IMMUPHARMA ATTENDING JP MORGAN CONFERENCE & BIOTECH SHOWCASE™
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO, will be attending both the JP Morgan Conference and the Biotech Showcase from 12-14 January 2026, in San Francisco, USA. The JP Morgan conference and Biotech Showcase are annual premier partnering events,…
-
Proactive
ImmuPharma CEO confident on P140 partnership as strong pharma interest extends timeline into 2026 28 November 2025 ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy talked with Proactive’s Stephen Gunnion about the company’s ongoing discussions to secure a partnership for its lead asset, P140 – November 2025
-
Sunday Roast
Midweek Takeaway featuring Tim McCarthy, CEO of ImmuPharma 26 November 2025 In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Tim McCarthy, CEO of ImmuPharma, for an in-depth update on the company’s P140 autoimmune platform. – November 2025
-
Corporate Update
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces an update on P140 partnership discussions. In the Corporate Update notification of 23 October 2025, ImmuPharma advised that it had started to engage with a number of potential partners on P140, and that the Company’s stated objective was to complete a deal by the…
-
TR1 from Lanstead – Major interest in shares
TR-1: Standard form for notification of major holdings from Lanstead To download form Click here
